| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Human DLL4 Protein, Fc Tag
Purity:>90% as determined by SDS-PAGE Package:50μg, 100μg
|
| Company Name: |
Shanghai Huzhen Industrial Co., LTD
|
| Tel: |
021-60345367 13916550749 |
| Email: |
sales@shzbio.com |
| Products Intro: |
Product Name:DLL4
Purity:> 99% Package:50ul/RMB 1098;100ul/RMB 1880;200ul/RMB 2900 Remarks:DeltaD; delta4; delta-like 4 (Drosophila); delta-like 4 homolog (Drosophila)
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:DLL4
Purity:95% SDS-PAGE Package:1mg;100ug
|
| Company Name: |
ACROBiosystems
|
| Tel: |
13121935750 |
| Email: |
jiaxin.zhao@acrobiosystems.com |
| Products Intro: |
Product Name:DLL4
|
| Company Name: |
DIMA
|
| Tel: |
400-006-0995 18062749453 |
| Email: |
info@dimabio.cn |
| Products Intro: |
Product Name:Human DLL4 Protein, His Tag
|
|
| Product Name: | DLL4 | | Synonyms: | DLL4;Human DLL4 Protein, Fc Tag;Human DLL4 Protein, His Tag;AOS6;hdelta2;PRO4341;UNQ1895 | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![DLL4 Structure]() |
| Description | The Notch pathway has been identified as one of the most commonly activated
pathways in cancer. This signaling cascade is crucial for cell growth, differentiation, and survival. Notch signaling has been identified as possibly having an impact in survival in those who have a diagnosis of cancer and thus
makes this a pathway of interest.
The Notch pathway is activated when a Notch receptor binds to a ligand. The
mammalian Notch family contains five ligands, delta-like ligand 1 (DLL1), deltalike ligand 3 (DLL3), delta-like ligand 4 (DLL4), Jagged-1 (JAG1), and Jagged-2
(JAG2), and four receptors, Notches 1–4. For the purpose of this review, we will
focus on DLL4, which has been studied in SCLC and implicated in activating NF-κβ
leading to enhanced VEGF secretion and promotion of metastases. | | Pharmacology | During tumorigenesis, induction of DLL4 expression by VEGF in endothelial
cells of the tumor leads to improved angiogenesis. Interruption of DLL4-Notch signaling led to suppression of tumor growth via nonproductive angiogenesis and
hypoxia of tumors. High levels of DLL4 are expressed in cancer stem cells in
preclinical models using SCLC cell lines. In human tumor xenografts, targeting
DLL4-Notch with anti-DLL4 monoclonal antibodies as a single agent or in
combination with cisplatin/etoposide or topotecan resulted in reduction of cancer
stem cells. |
| | DLL4 Preparation Products And Raw materials |
|